Trial Profile

An explorative Phase II trial of FG001 in patients with head and neck squamous cell carcinomas (HNSCC) undergoing surgery

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FG 001 (Primary)
Indications Carcinoma; Head and neck cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
Focus Proof of concept; Therapeutic Use

Most Recent Events

19 Nov 2024 According to a FluoGuide media release, data has been published in Theranostics.
19 Nov 2024 Primary endpoint (Sensitivity defined as the relative number of patients, where FG001 lights up the cancer confirmed by histopathology.) has been met, according to the Results published in the FluoGuide Media Release.
19 Nov 2024 Results present in the FluoGuide Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com